Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review

Abstract

Background Based on current evidence, recent guidelines of the National Institute of Health, USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 patients with mild-moderate disease, not requiring highflow oxygen. No therapeutic agent directed against the immunologic pathogenic mechanisms related to the cytokine release syndrome complicating the disease was indicated. Objectives The purpose of this review was to assess the clinical impact of different therapies for COVID-19; thus, helping to identify the optimal management of the disease. To explain the rationale for the different therapeutic approaches, the characteristics of SARS-CoV-2, the pathogenesis of COVID-19, and the immune response triggered by SARS-CoV-2 infection were reported. Methods The efficacy assessment of the different treatments was performed by a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available English language published articles including randomised controlled trials, open-label trials of antivirals and immune therapies extracted from Medline, Google Scholar, and MedRxiv databases were analysed. For inclusion, the primary end point of the trials had to be the efficacy as measured by the improvement of clinical features, or mortality, or the Intensive Care Unit Admission rate, or the discharge number. Case reports, paediatric studies, and studies without control group were excluded. The literature search was extended up to August 15, 2020. Results After the removal of duplicate articles, and the exclusion of studies not meeting the eligibility criteria, 2 trials of lopinavir/ritonavir, 1 of favipiravir, 3 of remdesivir, 1 of dexamethasone, 3 of hydroxychloroquine, 2 of colchicine, 6 of tocilizumab, 1 of sarilumab, 1 of siltuximab, 2 of anakinra, 3 of baricitinib, 1 of ruxolitinib, 1 of mavrilimumab, and 1 of itolizumab were suitable for the review. Among antivirals, only remdesivir significantly reduced the time to recovery, and mortality. Data for chloroquine and hydroxychloroquine were largely inconclusive. In a large trial, dexamethasone 6 mg/ day reduced mortality by one-third. Trials of tocilizumab and sarilumab did not definitively demonstrate efficacy. Anakinra significantly reduced the mortality in 2 trials. Three retrospective trials on a cumulative number of 145 patients, reported the efficacy of baricitinib, with significant reduction of intensive care unit admission, and deaths. These results were recently confirmed by the ACTT-2 trial. Due to paucity of studies and to the small size clinical series, the results of other immune therapies were not conclusive. Conclusions Beyond the supportive therapy, up to now the best therapeutic approach for COVID-19 may be a three-step combination therapy, including remdesivir 100 mg/day (200 mg loading dose on first day) in the first stage of the disease, and combined dexamethasone 6 mg/day plus baricitinib 4 mg/day to target the immune dysregulation triggered by the SARS-CoV-2 infection. ...

Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection

“…The presence of CHF was independently associated with all-cause death in our cohort (HR 2.3 CI95% (1.26–4.2), p = 0.007), confirming similar results recently published by Álvarez et al [ 11 ]. Interestingly, several treatments have been studied in COVID [ 23 , 24 , 25 , 26 ]. At the time this cohort was recruited, several anti-viral treatments, hydroxychloroquine plus azithromycin and tocilizumab were used, which have now been abandoned due to lack of efficacy.…”

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection

“…Point-of-care diagnostics tests to detect current SARS-CoV-2 infection have the potential to allow an earlier detection of infection, compared to laboratory-based diagnostic methods, thus contributing to the reduction of household and community transmission [ 8 – 10 ]. A rapid diagnosis is also crucial for setting up a good therapy [ 11 , 12 ]. In addition, they can be operated in near-patient settings rather than in the laboratory, which are expected to be more easily accessible and to relieve laboratory workload.…”

Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia

“…Virus lethality has been linked to the occurrence of a hyperinflammatory state or “cytokine storm” [2] characterised by abnormal production of proinflammatory cytokines which leads to respiratory failure and widespread tissue damage, resulting in multiorgan failure and death [3] . Therapies that target specific cytokines could improve survival rates from COVID-19, although results are variable and still preliminary [11] , [12] .…”

“…Increased cytokines recruit macrophages, neutrophils, and T-lymphocytes to the infection site, which can cause vascular barrier damage, capillary and endothelial damage, diffuse alveolar damage, multiorgan failure, and death [3] . The lungs are the main target organ of the hyperinflammatory state, and this process may progress into acute lung injury [12] . Although the mechanisms underlying severe pneumonia in COVID-19 patients are not yet fully understood, excessive proinflammatory cytokine production is considered to be one of the most important contributing factors [13] , [14] , [15] .…”